| Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers 2023 · Investigational medicinal product (IMP) · Adults with migraine meeting ICHD-3 classification criteria | 9 g | 12 weeks | 32 |
| Effect of Exogenous Ketones as an Adjunct to Low-Calorie Diet on Metabolic Markers 2025 · racemic β-hydroxybutyrate (BHB) mineral salts (BHB) · Adults aged 18–46 years with overweight or obesity (BMI 27–35 kg/m²), without the listed metabolic or cardiovascular diseases | 10 g | 8 weeks | 24 |
| Ketone monoester attenuates oxygen desaturation during weighted ruck exercise under acute hypoxic exposure but does not impact cognitive performance 2024 · KME condition · Healthy males aged 18–35 years | 573 mg/kg | 1 day | 16 |
| Exogenous Ketosis Impairs 30-min Time-Trial Performance Independent of Bicarbonate Supplementation 2021 · KE · Highly trained male cyclists, mean age 26 ± 6 years; no stated diagnosed condition | 50 g | 1 day | 12 |
| No effect of oral ketone ester supplementation on exercise capacity in patients with McArdle disease and healthy controls: A randomized placebo-controlled cross-over study 2022 · KE drink · Adults: patients with genetically verified glycogen storage disease type V and healthy controls; ages 25–70 years | 395 mg/kg | 1 day | 12 |
| Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1,3-Butanediol in Patients With Heart Failure With Reduced Ejection Fraction 2025 · 1,3-butanediol · Adults with heart failure with reduced ejection fraction, age 18 years or older; mean age 64 years; 75% male | 500 mg/kg | 1 day | 12 |
| Bicarbonate Unlocks the Ergogenic Action of Ketone Monoester Intake in Endurance Exercise 2021 · KE · Well-trained male cyclists, mean age 29 years; no stated diagnosed condition | 65 g | 1 day | 9 |
| Ketone Ester Supplementation Improves Some Aspects of Cognitive Function during a Simulated Soccer Match after Induced Mental Fatigue 2022 · KME · Healthy male recreational soccer players, mean age 30 ± 3 years | 25 g | 1 day | 9 |
| Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults 2021 · BH-BD group · Healthy adults aged 18–65 years | 12.5 g | 4 weeks | — |
| Exogenous Ketosis Impairs 30-min Time-Trial Performance Independent of Bicarbonate Supplementation 2021 · KE + BIC · Highly trained male cyclists, mean age 26 ± 6 years; no stated diagnosed condition | 50 g | 1 day | 12 |
| Bicarbonate Unlocks the Ergogenic Action of Ketone Monoester Intake in Endurance Exercise 2021 · KE + BIC · Well-trained male cyclists, mean age 29 years; no stated diagnosed condition | 65 g | 1 day | 9 |
| Increased cardiorespiratory stress during submaximal cycling after ketone monoester ingestion in endurance-trained adults 2021 · ketone monoester (KE) · endurance-trained adults; 10 males and 9 females | 600 mg/kg | 1 day | 19 |
| A Randomized Open-Label, Observational Study of the Novel Ketone Ester, Bis Octanoyl (R)-1,3-Butanediol, and Its Acute Effect on ß-Hydroxybutyrate and Glucose Concentrations in Healthy Older Adults 2025 · 12.5 g BO-BD beverage · Healthy community-dwelling adults aged 65 years or older, men and women, with stable chronic disease permitted | 12.5 g | 1 day | 15 |
| A Randomized Open-Label, Observational Study of the Novel Ketone Ester, Bis Octanoyl (R)-1,3-Butanediol, and Its Acute Effect on ß-Hydroxybutyrate and Glucose Concentrations in Healthy Older Adults 2025 · 25 g BO-BD beverage · Healthy community-dwelling adults aged 65 years or older, men and women, with stable chronic disease permitted | 25 g | 1 day | 15 |
| Tolerability and Acceptability of an Exogenous Ketone Monoester and Ketone Monoester/Salt Formulation in Humans 2023 · 5 g ketone monoester (KME5) · Adults aged 18–25 years with BMI 18.5–29.9 and no stated chronic disease | 5 g | 1 day | 14 |
| Tolerability and Acceptability of an Exogenous Ketone Monoester and Ketone Monoester/Salt Formulation in Humans 2023 · 10 g ketone monoester (KME10) · Adults aged 18–25 years with BMI 18.5–29.9 and no stated chronic disease | 10 g | 1 day | 14 |
| Tolerability and Acceptability of an Exogenous Ketone Monoester and Ketone Monoester/Salt Formulation in Humans 2023 · 5 g ketone monoester/salt (KMES5) · Adults aged 18–25 years with BMI 18.5–29.9 and no stated chronic disease | 5 g | 1 day | 14 |
| Tolerability and Acceptability of an Exogenous Ketone Monoester and Ketone Monoester/Salt Formulation in Humans 2023 · 10 g ketone monoester/salt (KMES10) · Adults aged 18–25 years with BMI 18.5–29.9 and no stated chronic disease | 10 g | 1 day | 14 |
| A Randomized Open-Label, Observational Study of the Novel Ketone Ester, Bis Octanoyl (R)-1,3-Butanediol, and Its Acute Effect on ß-Hydroxybutyrate and Glucose Concentrations in Healthy Older Adults 2025 · 12.5 g BO-BD powder · Healthy community-dwelling adults aged 65 years or older, men and women, with stable chronic disease permitted; subset who completed the 12-week study and re-consented | 12.5 g | 1 day | 12 |
| Low-Dose Ketone Monoester Administration in Adults with Cystic Fibrosis: A Pilot and Feasibility Study 2024 · KME · Adults aged 21–52 with cystic fibrosis, including inpatients with an acute pulmonary exacerbation and outpatients receiving standard care | 20 g | 7 days | 10 |
| A Randomized Open-Label, Observational Study of the Novel Ketone Ester, Bis Octanoyl (R)-1,3-Butanediol, and Its Acute Effect on ß-Hydroxybutyrate and Glucose Concentrations in Healthy Older Adults 2025 · 25 g BO-BD powder · Healthy community-dwelling adults aged 65 years or older, men and women, with stable chronic disease permitted; subset who completed the 12-week study and re-consented | 25 g | 1 day | 9 |
| The Effect of Novel Exogenous Ketone Supplements on Blood Beta-Hydroxybutyrate and Glucose 2024 · Ketone monoester · Healthy adults, mean age 29 ± 5 years; 42% female | 10 g | 1 day | — |
| Ketone monoester ingestion improves endothelial function during hyperglycemia in females with polycystic ovary syndrome 2026 · ketone monoester (KME) · Females with PCOS and age- and BMI-matched female controls; mean age 27 years in each group | 482 mg/kg | 1 day | 20 |
| Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial 2022 · KE arm · Healthy adults aged 18–60 without reported cardiovascular disease | 714 mg/kg | 1 day | 18 |
| The effect of a ketone monoester drink on blood glucose and substrate oxidation in adults with metabolic syndrome and matched controls 2025 · ketone ester (KE) condition · Adults aged 18–55, including participants with metabolic syndrome and matched participants without metabolic syndrome | 282 mg/kg | 1 day | 16 |
| Acute ingestion of a ketone monoester, whey protein, or their co-ingestion in the overnight postabsorptive state elicit a similar stimulation of myofibrillar protein synthesis rates in young males: a double-blind randomized trial 2024 · KET · Healthy recreationally active males, mean age 24.2 years, without a stated diagnosed condition | 360 mg/kg | 1 day | 12 |
| A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial 2024 · KME · Adults with type 2 diabetes, mean age 59 years; 50% female | 500 mg/kg | 1 day | 10 |
| Kinetics, tolerability and safety of (R)-1,3-butanediol (S)-lactate ester (LaKe): A randomized controlled cross-over trial in adults with obesity 2026 · LaKe · Otherwise healthy adults with obesity | 50 mL | 4 weeks | 10 |
| Ingestion of an exogenous ketone monoester improves the glycemic response during oral glucose tolerance test in individuals with impaired glucose tolerance: A cross-over randomized trial 2021 · ketone ester · Japanese adults aged 20–64 with impaired glucose tolerance; 5 men and 4 women, with BMI 18.5–25.0 kg/m² | 482 mg/kg | 1 day | 9 |
| Examining the Feasibility of Prolonged Beta-Hydroxybutyrate-Containing Supplement Drink Consumption in Adults with Type 2 Diabetes: A Randomized Controlled Pilot Trial 2025 · ketone · Adults living with type 2 diabetes | 30 g | 90 days | 20 |
| Acute ingestion of a ketone monoester, whey protein, or their co-ingestion in the overnight postabsorptive state elicit a similar stimulation of myofibrillar protein synthesis rates in young males: a double-blind randomized trial 2024 · KET+PRO · Healthy recreationally active males, mean age 24.2 years, without a stated diagnosed condition | 360 mg/kg | 1 day | 12 |
| Fasting and diurnal blood ketonemia and glycemia responses to a six-week, energy-controlled ketogenic diet, supplemented with racemic R/S-BHB salts 2023 · KD + KS · Non-diabetic adults with overweight or obesity | 24 g | 6 weeks | — |
| Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults 2021 · KD + KS · Adults aged 21–65 who were overweight or had class 1 obesity and wanted to lose weight; participants with chronic diseases were excluded. | 23.6 g | 6 weeks | 12 |